PTC: Ataluren, Clinical Trials, and Genetic Testing 101

Vinay Penematsa, MD
Medical Director, Clinical Development
[email protected]

Dr. Penematsa is the Medical Director and Clinical Lead for the nmDMD-Ataluren Program at PTC Therapeutics. He also supports the development of a new treatment for Mitochondrial diseases with Refractory epilepsy.

He graduated from Soochow University, in Suzhou, China in 2010. He trained at Gandhi Medical College, India where he completed his residency and practiced at Yashoda Hospitals and Little Star Children’s Hospital, Hyderabad, India.

He has interest in clinical research and committed to work towards the development of unmet medical needs in rare disease therapeutic areas. He has been involved in nmDMD clinical studies along with other indications, including Cystic Fibrosis, Huntington’s Disease, Mitochondrial Diseases with Refractory Epilepsy.

Ryan Miller, CGC
Director, Clinical Science and Diagnostics
[email protected]

As Director of Clinical Science and Diagnostics at PTC Therapeutics, Ryan works closely with biochemical and molecular laboratories to facilitate the early and accurate diagnosis of several rare genetic conditions. Prior to joining PTC last year, Ryan worked for over 5 years at Sanofi Genzyme focusing on lysosomal storage disorders. Before his move to industry, he spent 8 years working as a Genetic Counselor in a Pediatric Genetics clinic at SUNY Upstate in Syracuse, NY, seeing patients with a wide variety of genetic disorders. Ryan has an MS in Genetic Counseling from Mount Sinai School of Medicine and is a certified genetic counselor.